Charu Gandotra to Humans
This is a "connection" page, showing publications Charu Gandotra has written about Humans.
Connection Strength
0.120
-
Gandotra C, Clark J, Liu Q, Senatore FF, Rose M, Zhang J, Stockbridge NL. Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective. Ther Innov Regul Sci. 2022 01; 56(1):4-7.
Score: 0.038
-
Gandotra C, Basam M, Mahajan A, Ngwa J, Ortega G, Tran D, Fullum TM, Sherif ZA. Characteristics and resolution of hypertension in obese African American bariatric cohort. Sci Rep. 2021 01 18; 11(1):1683.
Score: 0.036
-
Wallach JD, Deng Y, Polley EC, Dhruva SS, Herrin J, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Jeffery MM, Lyon TD, Ross JS, McCoy RG. Assessing the use of observational methods and real-world data to emulate ongoing randomized controlled trials. Clin Trials. 2023 12; 20(6):689-698.
Score: 0.011
-
Deng Y, Polley EC, Wallach JD, Dhruva SS, Herrin J, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Lyon TD, Shah ND, Ross JS, McCoy RG. Emulating the GRADE trial using real world data: retrospective comparative effectiveness study. BMJ. 2022 10 03; 379:e070717.
Score: 0.010
-
Graham DJ, Izurieta HS, Muthuri SG, Zhang D, Sandhu AT, Lu Y, Zhao Y, Feng Y, Eworuke E, Lyu H, Gandotra C, Smith ER, Avagyan A, Wernecke M, Kelman JA, Forshee RA, MaCurdy TE. Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension. J Gen Intern Med. 2021 12; 36(12):3802-3809.
Score: 0.009
-
Wallach JD, Deng Y, McCoy RG, Dhruva SS, Herrin J, Berkowitz A, Polley EC, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Shah ND, Ross JS, Lyon TD. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Netw Open. 2021 10 01; 4(10):e2130587.
Score: 0.009
-
Patel T, Tesfaldet B, Gandotra C. Pooled patient level data are better suited than study level data to investigate the link between dipeptidyl peptidase-4 inhibitors and the risk of heart failure in type 2 diabetes. BMJ. 2016 May 24; 353:i2920.
Score: 0.007